Physician profile
Mark A Dombrowski
NPI 1043263916
$7,212.66
in general payments reported to CMS, 2019-2025
44 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,671 · 2020: $473 · 2021: $487 · 2022: $1,491 · 2023: $638 · 2024: $1,285 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066 · Education: $24.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.39 |
| Education | $24.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,263.11 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $946.39 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $474.59 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $453.77 | 2019-2023 | Rinvoq |
| Janssen Pharmaceuticals, INC | $338.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $338.52 | 2019-2025 | Capvaxive, Verquvo, Lagevrio |
| Medtronic, INC. | $326.14 | 2022-2024 | Signia, Appose Ulc |
| E.R. Squibb & Sons, L.L.C. | $279.71 | 2019-2022 | |
| Lilly USA, LLC | $258.85 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $245.55 | 2019-2025 | |
| Amarin Pharma, INC. | $188.82 | 2019-2021 | |
| Janssen Biotech, INC. | $184.97 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Tactile Systems Technology INC | $167.79 | 2025 | Flexitouch Plus, Nimbl |
| Asensus Surgical, INC. | $164.52 | 2022-2024 | Senhance |
| Abbott Laboratories | $148.43 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dombrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.